2026-05-05T10:30:44Zhttps://uvadoc.uva.es/oai/request

oai:uvadoc.uva.es:10324/516042025-03-07T08:38:45Zcom_10324_1181com_10324_931com_10324_894col_10324_1387

00925njm 22002777a 4500 dc Tamayo Velasco, Álvaro author Peñarrubia Ponce, María Jesús author Álvarez González, Francisco Javier author Gonzalo Benito, Hugo author Fuente, Ignacio de la author Martín Fernández, Marta author Eiros Bouza, José María author Martínez de Paz, Pedro José author Miramontes González, José Pablo author Fiz López, Aida author Arribas Rodríguez, Elisa author Cal Sabater, Paloma De La author Aller de la Fuente, Rocío author Dueñas Gutiérrez, Carlos Jesús author Heredia Rodríguez, María author Tamayo Gómez, Eduardo author Bernardo Ordiz, David author Gómez Sánchez, Esther author 2021 Antigen tests or polymerase chain reaction (PCR) amplification are currently COVID-19 diagnostic tools. However, developing complementary diagnosis tools is mandatory. Thus, we performed a plasma cytokine array in COVID-19 patients to identify novel diagnostic biomarkers. A discovery–validation study in two independent prospective cohorts was performed. The discovery cohort included 136 COVID-19 and non-COVID-19 patients recruited consecutively from 24 March to 11 April 2020. Forty-five cytokines’ quantification by the MAGPIX system (Luminex Corp., Austin, TX, USA) was performed in plasma samples. The validation cohort included 117 patients recruited consecutively from 15 to 25 April 2020 for validating results by ELISA. COVID-19 patients showed different levels of multiple cytokines compared to non-COVID-19 patients. A single chemokine, IP-10, accurately identified COVID-19 patients who required hospital admission (AUC: 0.962; 95%CI (0.933–0.992); p < 0.001)). The results were validated in an independent cohort by multivariable analysis (OR: 25.573; 95%CI (8.127–80.469); p < 0.001) and AUROC (AUC: 0.900; 95%CI (0.846–0.954); p < 0.001). Moreover, showing IP-10 plasma levels over 173.35 pg/mL identified COVID-19 with higher sensitivity (86.20%) than the first SARS-CoV-2 PCR. Our discover–validation study identified IP-10 as a robust biomarker in clinical practice for COVID-19 diagnosis at hospital. Therefore, IP-10 could be used as a complementary tool in clinical practice, especially in emergency departments. Journal of Personalized Medicine, 2021, vol. 11, n. 7, 681 2075-4426 https://uvadoc.uva.es/handle/10324/51604 10.3390/jpm11070681 Evaluation of cytokines as robust diagnostic biomarkers for COVID-19 detection